Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial

The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.

Continue in Briflio to read, react, comment, and share.